Search
Bolt Biotherapeutics Inc
BOLTAdd to Watchlist
3.990USD
+0.100+2.57%
Close 07-31 16:00（ET）Quotes delayed by 15 min
7.66MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Bolt Biotherapeutics Inc is 7.00, ranking 313 out of 385 in the Biotechnology & Medical Research industry. The average price target is 13.50, with a high of 75.00 and a low of 5.00.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
29.000
Target Price
+653.25%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Bolt Biotherapeutics Inc
BOLT
4
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Bolt Biotherapeutics Inc's expected revenue for the next quarter?
Bolt Biotherapeutics Inc's expected revenue is 500.00K.
What is Bolt Biotherapeutics Inc's price target?
Analysts forecast that Bolt Biotherapeutics Inc's price target is USD 13.50, with the highest forecast at USD 75.00 and the lowest forecast at USD 5.00.
How have Bolt Biotherapeutics IncBOLT's recent earnings per share performed?
The market expectation was USD -4.31, while Bolt Biotherapeutics IncBOLT's earnings per share (EPS) for the previous quarter was USD -3.84. EPS for the next quarter is expected at USD -3.39.
What is the analyst rating for Bolt Biotherapeutics Inc?
Based on the ratings of Bolt Biotherapeutics Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.